nach oben

Environmental Health and Preventive Medicine

Erschienen in:

01.09.2014 | Review

Silica exposure and altered regulation of autoimmunity

verfasst von: Suni Lee, Hidenori Matsuzaki, Naoko Kumagai-Takei, Kei Yoshitome, Megumi Maeda, Ying Chen, Masayasu Kusaka, Kozo Urakami, Hiroaki Hayashi, Wataru Fujimoto, Yasumitsu Nishimura, Takemi Otsuki

Erschienen in: Environmental Health and Preventive Medicine | Ausgabe 5/2014

Einloggen, um Zugang zu erhalten

Abstract

Silica particles and asbestos fibers, which are known as typical causatives of pneumoconiosis, induce lung fibrosis. Moreover, silicosis patients often complicate with autoimmune diseases, and asbestos-exposed patients suffer from malignant diseases such as pleural mesothelioma and lung cancer. We have been conducting experimental studies to investigate altered regulation of self-tolerance caused by silica exposure, including analyses using specimens such as plasma and immunocompetent cells obtained from silicosis patients, as a means of examining the supposition that silica exposure induces molecular and cellular biological alterations of immune cells. These approaches have resulted in the detection of several specific autoantibodies, alterations of CD95/Fas and its related molecules, and evidence of chronic activation of responder T cells and regulatory T cells following silica exposure. In this review, we present details of our investigations as an introduction to scientific approaches examining the immunological effects of environmental and occupational substances.

Cullinan P, Reid P. Pneumoconiosis. Prim Care Respir J. 2013;22:249–52.PubMedCrossRef

Laney AS, Weissman DN. The classic pneumoconioses: new epidemiological and laboratory observations. Clin Chest Med. 2012;33:745–58.PubMedCrossRef

Nukushina J. Japanese earthquake victims are being exposed to high density of asbestos. We need protective masks desperately. Epidemiol Prev. 1995;19:226–7.PubMed

van Orden DR, Lee RJ, Bishop KM, Kahane D, Morse R. Evaluation of ambient asbestos concentrations in buildings following the Loma Prieta earthquake. Regul Toxicol Pharmacol. 1995;21:117–22.PubMedCrossRef

Caplan A. Rheumatoid disease and pneumoconiosis (Caplan’s syndrome). Proc R Soc Med. 1959;52:1111–3.PubMedPubMedCentral

Caplan A, Payne A, Payne RB, Withey JL. A broader concept of Caplan’s syndrome related to rheumatoid factors. Thorax. 1962;17:205–12.PubMedCrossRefPubMedCentral

Costallat LT, De Capitani EM, Zambon L. Pulmonary silicosis and systemic lupus erythematosus in men: a report of two cases. Joint Bone Spine. 2002;69:68–71.PubMedCrossRef

Yamazaki S, Yoshiike F, Hirai K, Kakegawa T, Ikeda M, Nagata A, et al. Silica-associated systemic lupus erythematosus in an elderly man. Intern Med. 2007;46:1867–71.PubMedCrossRef

Haustein UF, Anderegg U. Silica induced scleroderma-clinical and experimental aspects. J Rheumatol. 1998;25:1917–26.PubMed

10.

Iannello S, Camuto M, Cantarella S, Cavaleri A, Ferriero P, Leanza A, Milazzo P, Belfiore F. Rheumatoid syndrome associated with lung interstitial disorder in a dental technician exposed to ceramic silica dust. A case report and critical literature review. Clin Rheumatol. 2002;21:76–81.PubMedCrossRef

11.

Tervaert JW, Stegeman CA, Kallenberg CG. Silicon exposure and vasculitis. Curr Opin Rheumatol. 1998;10:12–7.PubMedCrossRef

12.

Saeki T, Fujita N, Kourakata H, Yamazaki H, Miyamura S. Two cases of hypertrophic pachymeningitis associated with myeloperoxidase antineutrophil cytoplasmic autoantibody (MPO-ANCA)-positive pulmonary silicosis in tunnel workers. Clin Rheumatol. 2004;23:76–80.PubMedCrossRef

13.

Uber CL, McReynolds RA. Immunotoxicology of silica. Crit Rev Toxicol. 1982;10:303–19.PubMedCrossRef

14.

Steenland K, Goldsmith DF. Silica exposure and autoimmune diseases. Am J Ind Med. 1995;28:603–8.PubMedCrossRef

15.

Vera-Lastra O, Medina G, Del Pilar Cruz-Dominguez M, Jara LJ, Shoenfeld Y. Autoimmune/inflammatory syndrome induced by adjuvants (Shoenfeld’s syndrome): clinical and immunological spectrum. Expert Rev Clin Immunol. 2013;9:361–73.PubMedCrossRef

16.

Otsuki T, Maeda M, Murakami S, Hayashi H, Miura Y, Kusaka M, Nishimura Y, et al. Immunological effects of silica and asbestos. Cell Mol Immunol. 2007;4:261–8.PubMed

17.

Maeda M, Miura Y, Nishimura Y, Murakami S, Hayashi H, Kumagai N, et al. Immunological changes in mesothelioma patients and their experimental detection. Clin Med Circ Respir Pulm Med. 2008;2:11–7.

18.

Miura Y, Nishimura Y, Maeda M, Murakami S, Hayashi H, Fukuoka K, et al. Immunological alterations found in mesothelioma patients and supporting experimental evidence. Environ Health Prev Med. 2008;13:55–9.PubMedCrossRefPubMedCentral

19.

Murakami S, Nishimura Y, Maeda M, Kumagai N, Hayashi H, Chen Y, et al. Cytokine alteration and speculated immunological pathophysiology in silicosis and asbestos-related diseases. Environ Health Prev Med. 2009;14:216–22.PubMedCrossRefPubMedCentral

20.

ILO. Guideline for the use of the ILO international classification of radiographs of pneumoconiosis, Revised Edition 2000. ILO, Occupational Safety and Health series. No. 22. Geneva, Switzerland. 2002.

21.

Wu P, Miura Y, Hyodoh F, Nishimura Y, Hatayama T, Hatada S, et al. Reduced function of CD4 + 25 + regulatory T cell fraction in silicosis patients. Int J Immunopathol Pharmacol. 2006;19:357–68.PubMed

22.

Hayashi H, Maeda M, Murakami S, Kumagai N, Chen Y, Hatayama T, et al. Soluble interleukin-2 receptor as an indicator of immunological disturbance found 388 in silicosis patients. Int J Immunopathol Pharmacol. 2009;22:53–62.PubMed

23.

Ueki A, Isozaki Y, Tomokuni A, Tanaka S, Otsuki T, Kishimoto T, et al. Autoantibodies detectable in the sera of silicosis patients. The relationship between the anti-topoisomerase I antibody response and HLA-DQB1*0402 allele in Japanese silicosis patients. Sci Total Environ. 2001;270:141–8.PubMedCrossRef

24.

Ueki A, Isozaki Y, Tomokuni A, Ueki H, Kusaka M, Tanaka S, et al. Different distribution of HLA class II alleles in anti-topoisomerase I autoantibody responders between silicosis and systemic sclerosis patients, with a common distinct amino acid sequence in the HLA-DQB1 domain. Immunobiology. 2001;204:458–65.PubMedCrossRef

25.

Tomokuni A, Otsuki T, Sakaguchi H, Isozaki Y, Hyodoh F, Kusaka M, et al. Detection of anti-topoisomerase I autoantibody in patients with silicosis. Environ Health Prev Med. 2002;7:7–10.PubMedCrossRefPubMedCentral

26.

Ueki A, Isozaki Y, Tomokuni A, Otsuki T, Hyodoh F, Sakaguchi H, et al. Is the anti-topoisomerase I autoantibody response associated with a distinct amino acid sequence in the HLA-DQbeta1 domain? Arthritis Rheum. 2001;44:491–2.PubMedCrossRef

27.

Takata-Tomokuni A, Ueki A, Shiwa M, Isozaki Y, Hatayama T, Katsuyama H, et al. Detection, epitope-mapping and function of anti-Fas autoantibody in patients with silicosis. Immunology. 2005;116:21–9.PubMedCrossRefPubMedCentral

28.

Nagata S. Fas and Fas ligand: a death factor and its receptor. Adv Immunol. 1994;57:129–44.PubMedCrossRef

29.

Nagata S, Golstein P. The Fas death factor. Science. 1995;267:1449–56.PubMedCrossRef

30.

Bleesing JJ. Autoimmune lymphoproliferative syndrome (ALPS). Curr Pharm Des. 2003;9:265–78.PubMedCrossRef

31.

Rieux-Laucat F, Le Deist F, Fischer A. Autoimmune lymphoproliferative syndromes: genetic defects of apoptosis pathways. Cell Death Differ. 2003;10:124–33.PubMedCrossRef

32.

Peter ME, Krammer PH. Mechanisms of CD95 (APO-1/Fas)-mediated apoptosis. Curr Opin Immunol. 1998;10:545–51.PubMedCrossRef

33.

Cohen GM. Caspases: the executioners of apoptosis. Biochem J. 1997;326:1–16.PubMedPubMedCentral

34.

Ueki A, Isozaki Y, Tomokuni A, Hatayama T, Ueki H, Kusaka M, et al. Intramolecular epitope spreading among anti-caspase-8 autoantibodies in patients with silicosis, systemic sclerosis and systemic lupus erythematosus, as well as in healthy individuals. Clin Exp Immunol. 2002;129:556–61.PubMedCrossRefPubMedCentral

35.

Ueki A, Isozaki Y, Kusaka M. Anti-caspase-8 autoantibody response in silicosis patients is associated with HLA-DRB1, DQB1 and DPB1 alleles. J Occup Health. 2005;47:61–7.PubMedCrossRef

36.

Ueki H, Kohda M, Nobutoh T, Yamaguchi M, Omori K, Miyashita Y, et al. Antidesmoglein autoantibodies in silicosis patients with no bullous diseases. Dermatology. 2001;202:16–21.PubMedCrossRef

37.

Alderson MR, Lynch DH. Receptors and ligands that mediate activation-induced death of T cells. Springer Semin Immunopathol. 1998;19:289–300.PubMedCrossRef

38.

Mountz JD, Wu J, Zhou T, Hsu HC. Cell death and longevity: implications of Fas-mediated apoptosis in T-cell senescence. Immunol Rev. 1997;160:19–30.PubMedCrossRef

39.

Cascino I, Papoff G, Eramo A, Ruberti G. Soluble Fas/Apo-1 splicing variants and apoptosis. Front Biosci. 1996;1:d12–8.PubMed

40.

Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science. 1994;263:1759–62.PubMedCrossRef

41.

Knipping E, Krammer PH, Onel KB, Lehman TJ, Mysler E, Elkon KB. Levels of soluble Fas/APO-1/CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis. Arthritis Rheum. 1995;38:1735–7.PubMedCrossRef

42.

Tokano Y, Miyake S, Kayagaki N, Nozawa K, Morimoto S, Azuma M, et al. Soluble Fas molecule in the serum of patients with systemic lupus erythematosus. J Clin Immunol. 1996;16:261–5.PubMedCrossRef

43.

Jodo S, Kobayashi S, Kayagaki N, Ogura N, Feng Y, Amasaki Y, et al. Serum levels of soluble Fas/APO-1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases. Clin Exp Immunol. 1997;107:89–95.PubMedCrossRefPubMedCentral

44.

Nozawa K, Kayagaki N, Tokano Y, Yagita H, Okumura K, Hasimoto H. Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases. Arthritis Rheum. 1997;40:1126–9.PubMedCrossRef

45.

Tomokuni A, Aikoh T, Matsuki T, Isozaki Y, Otsuki T, Kita S, et al. Elevated soluble Fas/APO-1 (CD95) levels in silicosis patients without clinical symptoms of autoimmune diseases or malignant tumours. Clin Exp Immunol. 1997;110:303–9.PubMedCrossRefPubMedCentral

46.

Otsuki T, Sakaguchi H, Tomokuni A, Aikoh T, Matsuki T, Kawakami Y, et al. Soluble Fas mRNA is dominantly expressed in cases with silicosis. Immunology. 1998;94:258–62.PubMedCrossRefPubMedCentral

47.

Otsuki T, Sakaguchi H, Tomokuni A, Aikoh T, Matsuki T, Isozaki Y, et al. Detection of alternatively spliced variant messages of Fas gene and mutational screening of Fas and Fas ligand coding regions in peripheral blood mononuclear cells derived from silicosis patients. Immunol Lett. 2000;72:137–43.PubMedCrossRef

48.

Otsuki T, Tomokuni A, Sakaguchi H, Aikoh T, Matsuki T, Isozaki Y, et al. Over-expression of the decoy receptor 3 (DcR3) gene in peripheral blood mononuclear cells (PBMC) derived from silicosis patients. Clin Exp Immunol. 2000;119:323–7.PubMedCrossRefPubMedCentral

49.

Otsuki T, Miura Y, Nishimura Y, Hyodoh F, Takata A, Kusaka M, et al. Alterations of Fas and Fas-related molecules in patients with silicosis. Exp Biol Med (Maywood). 2006;231:522–33.

50.

Hayashi H, Miura Y, Maeda M, Murakami S, Kumagai N, Nishimura Y, et al. Reductive alteration of the regulatory function of the CD4(+)CD25(+) T cell fraction in silicosis patients. Int J Immunopathol Pharmacol. 2010;23:1099–109.PubMed

51.

Greene WC, Leonard WJ, Depper JM, Nelson DL, Waldmann TA. The human interleukin-2 receptor: normal and abnormal expression in T cells and in leukemias induced by the human T-lymphotropic retroviruses. Ann Intern Med. 1986;105:560–72.PubMedCrossRef

52.

Pizzolo G, Chilosi M, Semenzato G. The soluble interleukin-2 receptor in haematological disorders. Br J Haematol. 1987;67:377–80.PubMedCrossRef

53.

Zerler B. The soluble interleukin-2 receptor as a marker for human neoplasia and immune status. Cancer Cells. 1991;3:471–9.PubMed

54.

Witkowska AM. On the role of sIL-2R measurements in rheumatoid arthritis and cancers. Mediat Inflamm. 2005;2005:121–30.CrossRef

55.

Otsuki T, Ichihara K, Tomokuni A, Sakaguchi H, Aikoh T, Matsuki T, et al. Evaluation of cases with silicosis using the parameters related to Fas-mediated apoptosis. Int J Mol Med. 1999;4:407–11.PubMed

56.

Wu P, Hyodoh F, Hatayama T, Sakaguchi H, Hatada S, Miura Y, et al. Induction of CD69 antigen expression in peripheral blood mononuclear cells on exposure to silica, but not by asbestos/chrysotile-A. Immunol Lett. 2005;98:145–52.PubMedCrossRef

57.

Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell. 2000;101:455–8.PubMedCrossRef

58.

Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M, et al. Immunologic tolerance maintained by CD25 + CD4 + regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev. 2001;182:18–32.PubMedCrossRef

59.

Horwitz DA, Zheng SG, Gray JD, Wang JH, Ohtsuka K, Yamagiwa S. Regulatory T cells generated ex vivo as an approach for the therapy of autoimmune disease. Semin Immunol. 2004;16:135–43.PubMedCrossRef

60.

Sakaguchi S. Naturally arising Foxp3-expressing CD25 + CD4 + regulatory T cells in immunological tolerance to self and non-self. Nat Immunol. 2005;6:345–52.PubMedCrossRef

61.

Fritzsching B, Oberle N, Eberhardt N, Quick S, Haas J, Wildemann B, et al. In contrast to effector T cells, CD4 + CD25 + FoxP3 + regulatory T cells are highly susceptible to CD95 ligand- but not to TCR-mediated cell death. J Immunol. 2005;175:32–6.PubMedCrossRef

62.

Fritzsching B, Oberle N, Pauly E, Geffers R, Buer J, Poschl J, et al. Naive regulatory T cells: a novel subpopulation defined by resistance toward CD95L-mediated cell death. Blood. 2006;108:3371–8.PubMedCrossRef

63.

Otsuki T, Tomokuni A, Sakaguchi H, Hyodoh F, Kusaka M, Ueki A. Reduced expression of the inhibitory genes for Fas-mediated apoptosis in silicosis patients. J Occup Health. 2000;42:163–8.CrossRef

64.

Maeda M, Nishimura Y, Kumagai N, Hayashi H, Hatayama T, Katoh M, et al. Altered regulation of the immune system caused by silica and asbestos. J Immunotoxicol. 2010;7:268–78.PubMedCrossRef

65.

Lee S, Hayashi H, Maeda M, Chen Y, Matsuzaki H, Takei-Kumagai N, et al. Environmental factors producing autoimmune altered regulation–chronic activation of T cells caused by silica exposure. Immunobiology. 2012;217:743–8.PubMedCrossRef

66.

Takei-Kumagai N, Lee S, Matsuzaki H, Hayashi H, Maeda M, Nishimura Y, et al. Immunological effects of silica. In: Kretsinger RH, Uversky VN, Permyakov EA, editors. Encyclopedia of metalloproteins. New York: Springer Science + Business Media; 2013. pp. 1965–71.

67.

Kumagai N, Hayashi H, Maeda M, Miura Y, Nishimura Y, Matsuzaki H, et al. Immunological effects of silica and related altered regulation of autoimmunity. In: Mavragani CP, editor. Autoimmune disorders-pathogenetic aspects. Croatia: InTech Open Access Publisher; 2011. doi:10.5772/19218.

68.

Lee S, Maeda M, Hayashi H, Matsuzaki H, Kumagai-Takei N, Nishimura Y, et al. Immunostimulation by silica particles and the development of autoimmune altered regulation. In: Duc H, editor. Immunostimulation. Croatia: InTech Open Access Publisher; 2014. doi:10.5772/57544.

69.

Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity. 2006;24:677–88.PubMedCrossRef

70.

Bi Y, Liu G, Yang R. Th17 cell induction and immune regulatory effects. J Cell Physiol. 2007;211:273–8.PubMedCrossRef

Titel: Silica exposure and altered regulation of autoimmunity
verfasst von: Suni Lee
Hidenori Matsuzaki
Naoko Kumagai-Takei
Kei Yoshitome
Megumi Maeda
Ying Chen
Masayasu Kusaka
Kozo Urakami
Hiroaki Hayashi
Wataru Fujimoto
Yasumitsu Nishimura
Takemi Otsuki
Publikationsdatum: 01.09.2014
Verlag: Springer Japan
Erschienen in: Environmental Health and Preventive Medicine / Ausgabe 5/2014
Print ISSN: 1342-078X
Elektronische ISSN: 1347-4715
DOI: https://doi.org/10.1007/s12199-014-0403-9

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2014

Evaluation of the spread of pandemic influenza A/H1N1 2009 among Japanese university students

Non-thermal atmospheric pressure plasmas as a novel candidate for preventive therapy of melanoma

High iodine intake by preschool children in Miyagi prefecture, Japan

Circulating leptin levels are associated with physical activity or physical fitness in Japanese

Voluntary exercise under a food restriction condition decreases blood branched-chain amino acid levels, in addition to improvement of glucose and lipid metabolism, in db mice, animal model of type 2 diabetes

Sharps injuries in the operating room